Leveraging the Gut to Treat Metabolic Disease
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Twenty-five years ago, the future of treating obesity and diabetes focused on end organs known to be involved in energy balance and glucose regulation, including the brain, muscle, adipose tissue and pancreas. Today, the most effective therapies are focused around the gut. This includes surgical options, such as vertical sleeve gastrectomy and Roux-en-Y gastric bypass, that can produce sustained weight loss and diabetes remission, but also extends to pharmacological treatments that simulate or amplify various signals that come from the gut. The purpose of this review is to discuss the wealth of approaches currently under development that seek to further leverage the gut as a source of novel therapeutic opportunities with the hope that we can achieve the effects of surgical interventions with less invasive and more scalable solutions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta- analysis revealed that strategies that decrease glucose levels, especially those that decrease body weight, reduce the risk of the main adverse cardiovascular events, which proves the efficacy of diabetic therapies in ameliorating cardiovascular events.474”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [474]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity
Liou, A. P., Paziuk, M., Luevano, J.-M., Machineni, S., Turnbaugh, P. J., & Kaplan, L. M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005687 · Cited by 1,007
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
FXR is a molecular target for the effects of vertical sleeve gastrectomy
Ryan, K. K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Pérez, H. E., Sandoval, D. A., Kohli, R., Bäckhed, F., et al. (2014) · Nature · doi:10.1038/nature13135 · Cited by 931
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationKatsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789
Tremaroli, V., Karlsson, F., Werling, M., Ståhlman, M., Kovatcheva-Datchary, P., Olbers, T., Fändriks, L., le Roux, C. W., Nielsen, J., & Bäckhed, F. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.009 · Cited by 757
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Sensory neurons that detect stretch and nutrients in the digestive system
Williams, E. K., Chang, R. B., Strochlic, D. E., Umans, B. D., Lowell, B. B., & Liberles, S. D. (2016) · Cell · doi:10.1016/j.cell.2016.05.011 · Cited by 645
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Neuropeptide, Y, peptide YY and pancreatic polypeptide in the gut-brain axis
Holzer, P., Reichmann, F., & Farzi, A. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.08.005 · Cited by 501
Bile acid nuclear receptor FXR and digestive system diseases
Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Discovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Korner, J., Inabnet, W., Febres, G., Conwell, I. M., McMahon, D. J., Salas, R., Taveras, C., Schrope, B., & Bessler, M. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.79 · Cited by 338
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Murphy, R., Tsai, P., Jüllig, M., Liu, A., Plank, L., & Booth, M. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2399-2 · Cited by 285
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Self-citationKillion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation
Li, Y., Schnabl, K., Gabler, S.-M., Willershäuser, M., Reber, J., Karlas, A., Laurila, S., Lahesmaa, M., u Din, M., Bast-Habersbrunner, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.016 · Cited by 228
Holt, M. K., Richards, J. E., Cook, D. R., Brierley, D. I., Williams, D. L., Reimann, F., Gribble, F. M., & Trapp, S. (2019) · Diabetes · doi:10.2337/db18-0729 · Cited by 212
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038352 · Cited by 164
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159
Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132
Goldstone, A. P., Miras, A. D., Scholtz, S., Jackson, S., Neff, K. J., Pénicaud, L., Geoghegan, J., Chhina, N., Durighel, G., Bell, J. D., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2665 · Cited by 121
Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
The role of peptide YY in regulating glucose homeostasis
Boey, D., Sainsbury, A., & Herzog, H. (2007) · Peptides · doi:10.1016/j.peptides.2006.07.031 · Cited by 77
Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65
Sundström, L., Myhre, S., Sundqvist, M., Ahnmark, A., McCoull, W., Raubo, P., Groombridge, S. D., Polla, M., Nyström, A.-C., Kristensson, L., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189060 · Cited by 53
Oral semaglutide for the treatment of type 2 diabetes
Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1552258 · Cited by 44
Sloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Self-citation
Research works printed but not linked: 172
- Aaboe, 2009, KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 94, 603, 10.1210/jc.2008-1731 · DOI · Paper page
- Aaboe, 2010, Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus, Diabetes Obes. Metab., 12, 323, 10.1111/j.1463-1326.2009.01167.x · DOI
- Addy, 2016, Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus, Clin. Ther., 38, 516, 10.1016/j.clinthera.2015.12.020 · DOI
- Adrian, 1985, Human distribution and release of a putative new gut hormone, peptide YY, Gastroenterology, 89, 1070, 10.1016/0016-5085(85)90211-2 · DOI · Paper page
- Adrian, 1986, Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man, J. Clin. Endocrinol. Metab., 63, 803, 10.1210/jcem-63-4-803 · DOI · Paper page
- Ahlqvist, 2013, Link between GIP and osteopontin in adipose tissue and insulin resistance, Diabetes, 62, 2088, 10.2337/db12-0976 · DOI · Paper page
- Al-Najim, 2018, Food Intake and Eating Behavior After Bariatric Surgery, Physiol. Rev., 98, 1113, 10.1152/physrev.00021.2017 · DOI · Paper page
- Albaugh, 2019, Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery, Gastroenterology, 156, 1041, 10.1053/j.gastro.2018.11.017 · DOI · Paper page
- Arafat, 2013, Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?, Diabetologia, 56, 588, 10.1007/s00125-012-2803-y · DOI
- Araki, 2012, GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes, Diabetes Obes. Metab., 14, 271, 10.1111/j.1463-1326.2011.01525.x · DOI
- Arora, 2017, Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass, ISME J., 11, 2035, 10.1038/ismej.2017.70 · DOI
- Aulinger, 2014, Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade, Diabetes, 63, 1079, 10.2337/db13-1455 · DOI
- Azevedo, 2016, Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity, J. Med. Chem., 59, 8868, 10.1021/acs.jmedchem.6b00685 · DOI
- Behary, 2019, Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study, Diabetes Care, 42, 1446, 10.2337/dc19-0449 · DOI
- Boland, 2019, Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice, Mol. Metab., 25, 64, 10.1016/j.molmet.2019.05.004 · DOI
- Briere, 2015, Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice, PLoS ONE, 10, e0136873, 10.1371/journal.pone.0136873 · DOI
- Briere, 2018, Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery, Diabetes, 67, 309, 10.2337/db17-0607 · DOI
- Brown, 2012, Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist, ACS Med. Chem. Lett., 3, 726, 10.1021/ml300133f · DOI
- Calara, 2005, A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4), Clin. Ther., 27, 210, 10.1016/j.clinthera.2005.02.008 · DOI
- Capozzi, 2019, β Cell tone is defined by proglucagon peptides through cAMP signaling, JCI Insight, 4, 10.1172/jci.insight.126742 · DOI · Paper page
- Chambers, 2017, The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice, Cell Metab., 25, 927, 10.1016/j.cmet.2017.02.008 · DOI · Paper page
- Chen, 2016, GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space, Bioorg. Med. Chem. Lett., 26, 5603, 10.1016/j.bmcl.2016.10.074 · DOI
- Chepurny, 2018, Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors, Sci. Rep., 8, 3749, 10.1038/s41598-018-22106-1 · DOI
- Chisholm, 2002, Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures, Am. J. Physiol. Endocrinol. Metab., 283, E311, 10.1152/ajpendo.00434.2001 · DOI · Paper page
- Christensen, 2014, Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 99, E418, 10.1210/jc.2013-3644 · DOI · Paper page
- Christiansen, 2018, The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon, Am. J. Physiol. Gastrointest. Liver Physiol., 315, G53, 10.1152/ajpgi.00346.2017 · DOI · Paper page
- Chukir, 2018, Pharmacotherapy for obesity in individuals with type 2 diabetes, Expert Opin. Pharmacother., 19, 223, 10.1080/14656566.2018.1428558 · DOI
- Cohen, 2003, Oxyntomodulin suppresses appetite and reduces food intake in humans, J. Clin. Endocrinol. Metab., 88, 4696, 10.1210/jc.2003-030421 · DOI · Paper page
- Connolly, 2018, Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials, J. Clin. Transl. Hepatol., 6, 264
- Cox, 2016, Characterization and quantification of oxyntomodulin in human and rat plasma using high-resolution accurate mass LC-MS, Bioanalysis, 8, 1579, 10.4155/bio-2016-0012 · DOI
- Cox, 2016, Design, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists, ACS Med. Chem. Lett., 8, 49, 10.1021/acsmedchemlett.6b00360 · DOI
- D’Alessio, 1990, Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men, Diabetes, 39, 1198, 10.2337/diab.39.10.1198 · DOI
- Dar, 2012, GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)?, Obes. Surg., 22, 1077, 10.1007/s11695-012-0624-1 · DOI
- De Silva, 2011, The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans, Cell Metab., 14, 700, 10.1016/j.cmet.2011.09.010 · DOI · Paper page
- Deacon, 2016, Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas, Diabetes Obes. Metab., 18, 333, 10.1111/dom.12610 · DOI · Paper page
- Demssie, 2012, Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes, Med. Princ. Pract., 21, 125, 10.1159/000331793 · DOI
- Douros, 2018, Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor, Diabetes, 67, 1504, 10.2337/db18-0081 · DOI
- Dumont, 1995, Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands, J. Pharmacol. Exp. Ther., 272, 673, 10.1016/S0022-3565(25)24459-7 · DOI · Paper page
- Ellingsgaard, 2011, Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells, Nat. Med., 17, 1481, 10.1038/nm.2513 · DOI · Paper page
- Falkén, 2011, Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides, J. Clin. Endocrinol. Metab., 96, 2227, 10.1210/jc.2010-2876 · DOI · Paper page
- Farb, 2017, Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5, Endocrinology, 158, 3859, 10.1210/en.2017-00639 · DOI
- Fjellström, 2015, Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents, PLoS ONE, 10, e0145849, 10.1371/journal.pone.0145849 · DOI
- Frimurer, 2017, Model-Based Discovery of Synthetic Agonists for the Zn2+-Sensing G-Protein-Coupled Receptor 39 (GPR39) Reveals Novel Biological Functions, J. Med. Chem., 60, 886, 10.1021/acs.jmedchem.6b00648 · DOI
- García-Pérez, 2013, Adherence to therapies in patients with type 2 diabetes, Diabetes Ther., 4, 175, 10.1007/s13300-013-0034-y · DOI · Paper page
- Garibay, 2018, β Cell GLP-1R Signaling Alters α Cell Proglucagon Processing after Vertical Sleeve Gastrectomy in Mice, Cell Rep., 23, 967, 10.1016/j.celrep.2018.03.120 · DOI
- Gasoyan, 2019, Reasons for underutilization of bariatric surgery: The role of insurance benefit design, Surg. Obes. Relat. Dis., 15, 146, 10.1016/j.soard.2018.10.005 · DOI · Paper page
- Geary, 1992, Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men, Am. J. Physiol., 262, R975
- Geloneze, 2003, Ghrelin: a gut-brain hormone: effect of gastric bypass surgery, Obes. Surg., 13, 17, 10.1381/096089203321136539 · DOI · Paper page
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Gletsu-Miller, 2013, Mineral malnutrition following bariatric surgery, Adv. Nutr., 4, 506, 10.3945/an.113.004341 · DOI · Paper page
- Guida, 2018, Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY, Diabetes Obes. Metab., 20, 571, 10.1111/dom.13113 · DOI
- Günther, 2018, International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature, Pharmacol. Rev., 70, 763, 10.1124/pr.117.015388 · DOI · Paper page
- Guo, 2016, Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes, ACS Med. Chem. Lett., 7, 1107, 10.1021/acsmedchemlett.6b00314 · DOI
- Habib, 2013, Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells, Diabetologia, 56, 1413, 10.1007/s00125-013-2887-z · DOI · Paper page
- Hamdouchi, 2016, The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470), J. Med. Chem., 59, 10891, 10.1021/acs.jmedchem.6b00892 · DOI
- Hankir, 2017, Gastric Bypass Surgery Recruits a Gut PPAR-α-Striatal D1R Pathway to Reduce Fat Appetite in Obese Rats, Cell Metab., 25, 335, 10.1016/j.cmet.2016.12.006 · DOI
- Hansen, 2000, Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum, Am. J. Physiol. Endocrinol. Metab., 278, E1010, 10.1152/ajpendo.2000.278.6.E1010 · DOI · Paper page
- Hauge-Evans, 2009, Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function, Diabetes, 58, 403, 10.2337/db08-0792 · DOI · Paper page
- Henderson, 2016, Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates, Diabetes Obes. Metab., 18, 1176, 10.1111/dom.12735 · DOI · Paper page
- Henry, 2013, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers, J. Clin. Endocrinol. Metab., 98, 3446, 10.1210/jc.2013-1771 · DOI · Paper page
- Herman, 2006, Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 91, 4612, 10.1210/jc.2006-1009 · DOI · Paper page
- Hirose, 2017, Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus, Bioorg. Med. Chem., 25, 4175, 10.1016/j.bmc.2017.06.007 · DOI
- Hjøllund, 2011, Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs, Diabetologia, 54, 2206, 10.1007/s00125-011-2168-7 · DOI
- Holst, 2018, Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss, Surg. Obes. Relat. Dis., 14, 708, 10.1016/j.soard.2018.03.003 · DOI · Paper page
- Hornigold, 2018, A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice, Appetite, 127, 334, 10.1016/j.appet.2018.05.131 · DOI · Paper page
- Jordan, 2008, Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients, Clin. Pharmacol. Ther., 83, 281, 10.1038/sj.clpt.6100272 · DOI · Paper page
- Kaku, 2016, Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study, Diabetes Obes. Metab., 18, 925, 10.1111/dom.12693 · DOI
- Kalinowski, 2017, Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass-results of a randomized clinical trial, Surg. Obes. Relat. Dis., 13, 181, 10.1016/j.soard.2016.08.025 · DOI
- Kassem, 2017, The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus and the Management of Hypoglycemic Events, Front. Endocrinol. (Lausanne), 8, 37, 10.3389/fendo.2017.00037 · DOI
- Katz, 2011, Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects, Clin. Pharmacol. Ther., 90, 685, 10.1038/clpt.2011.169 · DOI
- Katz, 2012, Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes, Diabetes Obes. Metab., 14, 709, 10.1111/j.1463-1326.2012.01587.x · DOI · Paper page
- Keitel, 2009, The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders, Hepatology, 50, 861, 10.1002/hep.23032 · DOI · Paper page
- Kim, 2018, Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21, Diabetes, 67, 1773, 10.2337/db17-1502 · DOI · Paper page
- Kjaergaard, 2019, PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice, Neuropeptides, 73, 89, 10.1016/j.npep.2018.11.004 · DOI
- Kliewer, 2019, A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21, Cell Metab., 29, 246, 10.1016/j.cmet.2019.01.004 · DOI · Paper page
- Knop, 2017, Exenatide: pharmacokinetics, clinical use, and future directions, Expert Opin. Pharmacother., 18, 555, 10.1080/14656566.2017.1282463 · DOI
- Kojima, 1999, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature, 402, 656, 10.1038/45230 · DOI · Paper page
- Kosinski, 2012, The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin, Obesity (Silver Spring), 20, 1566, 10.1038/oby.2012.67 · DOI · Paper page
- Kothare, 2008, Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus, J. Clin. Pharmacol., 48, 1389, 10.1177/0091270008323750 · DOI
- Krug, 2017, Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection, Clin. Transl. Sci., 10, 404, 10.1111/cts.12479 · DOI
- Lee, 2016, Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test, Clin. Chem., 62, 227, 10.1373/clinchem.2015.244251 · DOI
- Li, 2011, The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling, Mol. Endocrinol., 25, 1066, 10.1210/me.2010-0460 · DOI · Paper page
- Li, 2016, Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development, Expert Opin. Investig. Drugs, 25, 871, 10.1080/13543784.2016.1189530 · DOI
- Lim, 2019, Correlation Between Symptomatic Gastro-Esophageal Reflux Disease (GERD) and Erosive Esophagitis (EE) Post-vertical Sleeve Gastrectomy (VSG), Obes. Surg., 29, 207, 10.1007/s11695-018-3509-0 · DOI
- Lin, 2004, The effects of gastric surgery on systemic ghrelin levels in the morbidly obese, Arch. Surg., 139, 780, 10.1001/archsurg.139.7.780 · DOI
- Lin, 2012, Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor, Mol. Pharmacol., 82, 843, 10.1124/mol.112.079640 · DOI
- Lin, 2016, GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism, PLoS ONE, 11, e0157298, 10.1371/journal.pone.0157298 · DOI · Paper page
- Lin, 2018, GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function, Mol. Metab., 11, 205, 10.1016/j.molmet.2018.02.008 · DOI
- Liu, 2018, Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition, ACS Med. Chem. Lett., 9, 1082, 10.1021/acsmedchemlett.8b00305 · DOI
- Lu, 2017, Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40, Nat. Struct. Mol. Biol., 24, 570, 10.1038/nsmb.3417 · DOI · Paper page
- Lund, 2016, Evidence of Extrapancreatic Glucagon Secretion in Man, Diabetes, 65, 585, 10.2337/db15-1541 · DOI · Paper page
- Lundberg, 1982, Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility, Proc. Natl. Acad. Sci. USA, 79, 4471, 10.1073/pnas.79.14.4471 · DOI · Paper page
- Luo, 2012, A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents, PLoS ONE, 7, e46300, 10.1371/journal.pone.0046300 · DOI
- Luo, 2018, The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Clin. Drug Investig., 38, 1089, 10.1007/s40261-018-0707-4 · DOI
- Malhi, 2017, Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases, Curr. Opin. Pharmacol., 37, 80, 10.1016/j.coph.2017.09.008 · DOI
- Martin, 1996, Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep, J. Endocrinol., 151, 107, 10.1677/joe.0.1510107 · DOI
- Matsumoto, 2018, DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats, J. Pharmacol. Exp. Ther., 367, 509, 10.1124/jpet.118.250019 · DOI
- McGavigan, 2017, TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice, Gut, 66, 226, 10.1136/gutjnl-2015-309871 · DOI · Paper page
- Medeiros, 1994, Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11, Endocrinology, 134, 2088, 10.1210/endo.134.5.7908871 · DOI
- Meegalla, 2018, Discovery of a novel potent GPR40 full agonist, Bioorg. Med. Chem. Lett., 28, 720, 10.1016/j.bmcl.2018.01.013 · DOI
- Meneilly, 1993, The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide, Diabetes Care, 16, 110, 10.2337/diacare.16.1.110 · DOI
- Menon, 2018, Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial, Diabetes Care, 41, 2603, 10.2337/dc18-0755 · DOI
- Mentlein, 1993, Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV, Regul. Pept., 49, 133, 10.1016/0167-0115(93)90435-B · DOI · Paper page
- Miller, 2016, Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target, Trends Endocrinol. Metab., 27, 609, 10.1016/j.tem.2016.04.002 · DOI
- Miras, 2017, Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans, Obes. Sci. Pract., 3, 95, 10.1002/osp4.76 · DOI
- Mokadem, 2013, Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency, Mol. Metab., 3, 191, 10.1016/j.molmet.2013.11.010 · DOI · Paper page
- Mulvihill, 2018, Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism, Peptides, 100, 158, 10.1016/j.peptides.2017.11.023 · DOI
- Näslund, 1997, Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity, Int. J. Obes. Relat. Metab. Disord., 21, 387, 10.1038/sj.ijo.0800418 · DOI · Paper page
- Nasteska, 2014, Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions, Diabetes, 63, 2332, 10.2337/db13-1563 · DOI · Paper page
- Neary, 2005, Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively, Endocrinology, 146, 5120, 10.1210/en.2005-0237 · DOI · Paper page
- Neylon, 2013, Successful subcutaneous glucagon use for persistent hypoglycaemia in congenital hyperinsulinism, J. Pediatr. Endocrinol. Metab., 26, 1157
- Nørregaard, 2018, A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents, Diabetes Obes. Metab., 20, 60, 10.1111/dom.13034 · DOI · Paper page
- Nunez, 2014, Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies, PLoS ONE, 9, e92494, 10.1371/journal.pone.0092494 · DOI · Paper page
- O’Carroll, 1992, Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28, Mol. Pharmacol., 42, 939, 10.1016/S0026-895X(25)09269-7 · DOI · Paper page
- Oh, 2014, A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice, Nat. Med., 20, 942, 10.1038/nm.3614 · DOI · Paper page
- Østergaard, 2018, Design of Y2 Receptor Selective and Proteolytically Stable PYY3-36 Analogues, J. Med. Chem., 61, 10519, 10.1021/acs.jmedchem.8b01046 · DOI
- Overton, 2006, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents, Cell Metab., 3, 167, 10.1016/j.cmet.2006.02.004 · DOI · Paper page
- Pachanski, 2017, GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent, PLoS ONE, 12, e0186033, 10.1371/journal.pone.0186033 · DOI
- Patel, 1999, Somatostatin and its receptor family, Front. Neuroendocrinol., 20, 157, 10.1006/frne.1999.0183 · DOI · Paper page
- Patel, 1978, Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat, Endocrinology, 102, 523, 10.1210/endo-102-2-523 · DOI · Paper page
- Pellicciari, 2009, Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity, J. Med. Chem., 52, 7958, 10.1021/jm901390p · DOI · Paper page
- Penick, 1961, Depression of food intake induced in healthy subjects by glucagon, N. Engl. J. Med., 264, 893, 10.1056/NEJM196105042641801 · DOI
- Peukert, 2014, Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists, ACS Med. Chem. Lett., 5, 1114, 10.1021/ml500240d · DOI
- Pittner, 2004, Effects of PYY[3-36] in rodent models of diabetes and obesity, Int. J. Obes. Relat. Metab. Disord., 28, 963, 10.1038/sj.ijo.0802696 · DOI · Paper page
- Plamboeck, 2013, The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty, Am. J. Physiol. Gastrointest. Liver Physiol., 304, G1117, 10.1152/ajpgi.00035.2013 · DOI · Paper page
- Pocai, 2012, Unraveling oxyntomodulin, GLP1's enigmatic brother, J. Endocrinol., 215, 335, 10.1530/JOE-12-0368 · DOI
- Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
- Polonsky, 1983, Plasma somatostatin 28 increases in response to feeding in man, J. Clin. Invest., 71, 1514, 10.1172/JCI110907 · doi:10.1172/jci110907
- Rangwala, 2019, A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates, Cell Metab., 29, 837, 10.1016/j.cmet.2019.01.017 · DOI · Paper page
- Rao, 2011, GIP and bariatric surgery, Obes. Surg., 21, 244, 10.1007/s11695-010-0305-x · DOI
- Ratner, 2016, Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery, Endocrinology, 157, 3482, 10.1210/en.2016-1329 · DOI
- Ratner, 2019, Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway, Diabetes, 68, 1329, 10.2337/db18-1009 · DOI · Paper page
- Rigamonti, 2011, Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity, Eur. J. Endocrinol., 165, 421, 10.1530/EJE-11-0312 · DOI
- Ritter, 2016, G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges, J. Med. Chem., 59, 3579, 10.1021/acs.jmedchem.5b01198 · DOI · Paper page
- Rudenko, 2019, The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones, Mol. Metab., 19, 49, 10.1016/j.molmet.2018.10.012 · DOI
- Salehi, 2016, Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe, Surg. Obes. Relat. Dis., 12, 1230, 10.1016/j.soard.2016.05.008 · DOI
- Salehi, 2019, Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery, Gut, 68, 1838, 10.1136/gutjnl-2018-317760 · DOI
- Schalla, 2019, Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges, Curr. Diab. Rep., 19, 102, 10.1007/s11892-019-1211-9 · DOI
- Schellekens, 2010, Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity, Neuropharmacology, 58, 2, 10.1016/j.neuropharm.2009.06.024 · DOI
- Schilperoort, 2018, The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat, EMBO Mol. Med., 10, e8047, 10.15252/emmm.201708047 · DOI
- Schmidt, 2014, Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men, Am. J. Physiol. Endocrinol. Metab., 306, E1248, 10.1152/ajpendo.00569.2013 · DOI · Paper page
- Seeley, 2015, The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes, Cell Metab., 21, 369, 10.1016/j.cmet.2015.01.001 · DOI · Paper page
- Semple, 2011, Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control, Bioorg. Med. Chem. Lett., 21, 3134, 10.1016/j.bmcl.2011.03.007 · doi:10.1016/j.bmcl.2011.03.007
- Shankar, 2018, Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes, Diabetes, 67, 1105, 10.2337/db17-1331 · DOI
- Shen, 1982, Human somatostatin I: sequence of the cDNA, Proc. Natl. Acad. Sci. USA, 79, 4575, 10.1073/pnas.79.15.4575 · DOI · Paper page
- Sheng, 2018, Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design, Bioorg. Med. Chem. Lett., 28, 2599, 10.1016/j.bmcl.2018.06.047 · doi:10.1016/j.bmcl.2018.06.047
- Shi, 2018, Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists, J. Med. Chem., 61, 681, 10.1021/acs.jmedchem.7b00982 · DOI
- Sparks, 2017, Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist, Bioorg. Med. Chem. Lett., 27, 1278, 10.1016/j.bmcl.2017.01.034 · DOI
- Sumida, 2018, Current and future pharmacological therapies for NAFLD/NASH, J. Gastroenterol., 53, 362, 10.1007/s00535-017-1415-1 · DOI · Paper page
- Talsania, 2005, Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice, Endocrinology, 146, 3748, 10.1210/en.2005-0473 · DOI · Paper page
- Tan, 2004, Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome, J. Clin. Endocrinol. Metab., 89, 4162, 10.1210/jc.2004-0835 · DOI · Paper page
- Tatemoto, 1982, Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion, Proc. Natl. Acad. Sci. USA, 79, 2514, 10.1073/pnas.79.8.2514 · DOI · Paper page
- Tatemoto, 1980, Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides, Nature, 285, 417, 10.1038/285417a0 · DOI · Paper page
- Tillner, 2019, A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials, Diabetes Obes. Metab., 21, 120, 10.1111/dom.13494 · DOI · Paper page
- Toda, 2013, Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes, ACS Med. Chem. Lett., 4, 790, 10.1021/ml400186z · DOI
- Tsilingiris, 2019, Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: Fact or Fiction?, Int. J. Environ. Res. Public Health, 16, 3171, 10.3390/ijerph16173171 · DOI
- Tuttle, 2018, Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial, Lancet Diabetes Endocrinol., 6, 605, 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
- van den Hoek, 2004, PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet, Diabetes, 53, 1949, 10.2337/diabetes.53.8.1949 · DOI · Paper page
- Vilsbøll, 2003, The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype, J. Clin. Endocrinol. Metab., 88, 4897, 10.1210/jc.2003-030738 · DOI · Paper page
- Vu, 2001, Effect of somatostatin on postprandial gallbladder relaxation, Clin. Physiol., 21, 25, 10.1046/j.1365-2281.2001.00297.x · doi:10.1046/j.1365-2281.2001.00297.x
- Wacker, 2014, Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119, J. Med. Chem., 57, 7499, 10.1021/jm501175v · DOI
- Wewer Albrechtsen, 2016, Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma, EBioMedicine, 7, 112, 10.1016/j.ebiom.2016.03.034 · DOI
- Willard, 2012, Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin, Mol. Pharmacol., 82, 1066, 10.1124/mol.112.080432 · DOI
- Wilson, 2016, Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes, Bioorg. Med. Chem. Lett., 26, 2947, 10.1016/j.bmcl.2016.04.018 · DOI
- Wilson-Pérez, 2013, Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency, Diabetes, 62, 2380, 10.2337/db12-1498 · DOI · Paper page
- Wilson-Pérez, 2013, The effect of vertical sleeve gastrectomy on food choice in rats, Int. J. Obes., 37, 288, 10.1038/ijo.2012.18 · DOI
- Winters, 2018, Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes, Bioorg. Med. Chem. Lett., 28, 841, 10.1016/j.bmcl.2018.02.013 · DOI
- Yamada, 2018, Weekly Versus Daily Dipeptidyl Peptidase 4 Inhibitor Therapy for Type 2 Diabetes: Systematic Review and Meta-analysis, Diabetes Care, 41, e52, 10.2337/dc17-2095 · doi:10.2337/dc17-2095
- Yamada, 2018, Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study, Adv. Ther., 35, 367, 10.1007/s12325-018-0668-2 · DOI
- Yousseif, 2014, Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans, Obes. Surg., 24, 241, 10.1007/s11695-013-1066-0 · DOI · Paper page
- Yu, 2013, Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies, ACS Med. Chem. Lett., 4, 829, 10.1021/ml4000854 · DOI
- Zhang, 2017, Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes, ACS Med. Chem. Lett., 8, 947, 10.1021/acsmedchemlett.7b00233 · doi:10.1021/acsmedchemlett.7b00233
Cited by
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
Self-citationOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
The role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
A Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Metadata
- Authors
- Gimeno, R. E., Briere, D. A., & Seeley, R. J.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 31
- Issue
- 4
- Pages
- 679-698
- ISSN
- 1550-4131
- Cited by
- 83
- References
- 77
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 371 d)
- Funders
- Sanofi
- Zafgen
- Pfizer
- Novo Nordisk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.